Glenmark receives ANDA approval for generic version of Micardis® HCT Tablets
05 March 2019 | News
Glenmark’s current portfolio consists of 150 products authorized for distribution in the U.S. marketplace
Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Telmisartan and Hydrochlorothiazide Tablets USP, 40 mg/12.5 mg, 80 mg/12.5 mg, and 80 mg/25 mg, a generic version of Micardis®1 HCT Tablets, of Boehringer Ingelheim Pharmaceuticals, Inc.
According to IQVIATM sales data for the 12 month period ending January 2019, the Micardis® HCT Tablets market achieved annual sales of approximately $40.6 million.
Glenmark’s current portfolio consists of 150 products authorized for distribution in the U.S. marketplace and 52 ANDA’s pending approval with the U.S. FDA.
